Compare TGLS & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | ADPT |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2011 | 2019 |
| Metric | TGLS | ADPT |
|---|---|---|
| Price | $42.13 | $16.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $63.33 | $17.78 |
| AVG Volume (30 Days) | 305.4K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $370,984,000.00 | $276,976,000.00 |
| Revenue This Year | $13.56 | $3.98 |
| Revenue Next Year | $9.04 | $22.72 |
| P/E Ratio | $60.20 | ★ N/A |
| Revenue Growth | 17.98 | ★ 54.77 |
| 52 Week Low | $37.52 | $9.96 |
| 52 Week High | $89.66 | $20.76 |
| Indicator | TGLS | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 63.49 |
| Support Level | $40.35 | $16.55 |
| Resistance Level | $46.41 | $17.52 |
| Average True Range (ATR) | 1.62 | 0.90 |
| MACD | 0.24 | 0.38 |
| Stochastic Oscillator | 54.21 | 72.62 |
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.